GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Return-on-Tangible-Asset

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Return-on-Tangible-Asset : 7.10% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Biocytogen Pharmaceuticals (Beijing) Co's annualized Net Income for the quarter that ended in Dec. 2024 was €22.1 Mil. Biocytogen Pharmaceuticals (Beijing) Co's average total tangible assets for the quarter that ended in Dec. 2024 was €311.2 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was 7.10%.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Return-on-Tangible-Asset or its related term are showing as below:

FRA:I54' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -24   Med: -18.42   Max: 1.38
Current: 1.36

During the past 5 years, Biocytogen Pharmaceuticals (Beijing) Co's highest Return-on-Tangible-Asset was 1.38%. The lowest was -24.00%. And the median was -18.42%.

FRA:I54's Return-on-Tangible-Asset is ranked better than
83.59% of 1499 companies
in the Biotechnology industry
Industry Median: -37.87 vs FRA:I54: 1.36

Biocytogen Pharmaceuticals (Beijing) Co Return-on-Tangible-Asset Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Return-on-Tangible-Asset Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
-18.42 -24.80 -23.49 -14.34 1.41

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only -26.20 -13.57 -15.10 -4.19 7.10

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Return-on-Tangible-Asset

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Return-on-Tangible-Asset falls into.


;
;

Biocytogen Pharmaceuticals (Beijing) Co Return-on-Tangible-Asset Calculation

Biocytogen Pharmaceuticals (Beijing) Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=4.4/( (310.959+314.103)/ 2 )
=4.4/312.531
=1.41 %

Biocytogen Pharmaceuticals (Beijing) Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=22.092/( (308.328+314.103)/ 2 )
=22.092/311.2155
=7.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2024) net income data.


Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Biocytogen Pharmaceuticals (Beijing) Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines